Welcome to our dedicated page for Checkpoint Therapeutics SEC filings (Ticker: CKPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Checkpoint Therapeutics, Inc. (CKPT) provides access to the company’s official U.S. regulatory disclosures as it advances immunotherapy and targeted oncology programs. Checkpoint describes itself as a commercial-stage company focused on solid tumor cancers, with an FDA-approved PD-L1–blocking antibody, UNLOXCYT™ (cosibelimab-ipdl), for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation, and an investigational EGFR inhibitor, olafertinib (formerly CK-101), in development for EGFR mutation-positive non-small cell lung cancer.
Through its SEC reports, investors can review details that complement these public descriptions, including information on product development activities, risk factors related to regulatory review of biologics such as cosibelimab, dependence on third-party contract manufacturing organizations, financing transactions, and other matters relevant to an oncology-focused pharmaceutical preparation manufacturer.
Stock Titan enhances this information by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. When Checkpoint files annual reports on Form 10-K or quarterly reports on Form 10-Q, AI tools help explain complex sections, such as discussions of clinical programs, manufacturing arrangements, and liquidity. Current reports on Form 8-K related to events like financing agreements, collaboration arrangements, or the announced Agreement and Plan of Merger with Sun Pharmaceutical Industries, Inc. can be quickly understood through concise AI-generated highlights.
Insider transaction filings on Form 4, when available, are also surfaced with clear context so users can see how directors, officers, or significant stockholders are trading CKPT shares. Proxy statements can provide additional insight into governance and equity-based compensation structures at a company founded by Fortress Biotech, Inc. By consolidating these documents and layering AI explanations on top, the filings page helps users navigate Checkpoint’s regulatory history and corporate disclosures without having to parse every technical detail themselves.
Checkpoint Therapeutics received a Schedule 13G/A filing from Beryl Capital and affiliated entities reporting they do not beneficially own any shares of the company's common stock. The filing shows 0 shares held and 0% of the class and explicitly states the reporting persons disclaim beneficial ownership except for any pecuniary interest.
The filing identifies the reporting parties as an investment adviser and related partnerships, confirms the position is reported as "5 percent or less of a class," and includes certifications that the securities were not acquired to influence control. Signatures from Beryl's COO and David A. Witkin are included.